Edwards Lifesciences Corporation (EW) Shares Sold by Advisors Asset Management Inc.
Advisors Asset Management Inc. cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 16.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,730 shares of the medical research company’s stock after selling 6,829 shares during the period. Advisors Asset Management Inc.’s holdings in Edwards Lifesciences Corporation were worth $3,687,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. ETF Managers Group LLC purchased a new position in Edwards Lifesciences Corporation during the second quarter valued at approximately $112,000. Shine Investment Advisory Services Inc. purchased a new position in Edwards Lifesciences Corporation during the second quarter valued at approximately $126,000. Cornerstone Advisors Inc. grew its position in Edwards Lifesciences Corporation by 25.1% during the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares in the last quarter. Alexandria Capital LLC grew its position in Edwards Lifesciences Corporation by 1.7% during the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new position in Edwards Lifesciences Corporation during the second quarter valued at approximately $140,000. 82.16% of the stock is currently owned by hedge funds and other institutional investors.
Edwards Lifesciences Corporation (NYSE:EW) opened at $108.81 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45. The stock has a market cap of $23,176.61, a PE ratio of 30.34, a price-to-earnings-growth ratio of 1.96 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. equities research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.
A number of analysts have recently weighed in on the stock. Barclays PLC restated an “equal weight” rating and issued a $120.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Saturday, September 30th. Canaccord Genuity restated a “buy” rating and issued a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a research note on Sunday, July 30th. Cowen and Company restated an “outperform” rating and issued a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Stifel Nicolaus restated a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $125.17.
In related news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $106.86, for a total value of $3,515,694.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 191,440 shares of company stock worth $20,645,937. Corporate insiders own 2.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/edwards-lifesciences-corporation-ew-shares-sold-by-advisors-asset-management-inc/1721779.html.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.